Turning Point Therapeutics

$106.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.47 (+1.41%) Today

$0.00 (0.00%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can buy or sell TPTX and other stocks, options, and ETFs commission-free!

About TPTX

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. The listed name for TPTX is Turning Point Therapeutics, Inc. Common Stock.

CEO

Athena Countouriotis

Employees

Headquarters

San Diego, California

Founded

2013

Market Cap

5.11B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

326.84K

High Today

$107.10

Low Today

$103.48

Open Price

$105.29

Volume

145.12K

52 Week High

$122.85

52 Week Low

$31.30

Collections

Analyst Ratings

100%

of 9 ratings

Buy

100%

Hold

Sell

TPTX Earnings

-$0.89

-$0.73

-$0.58

-$0.42

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Estimated

-$0.54 per share

Actual

-$0.42 per share